$0.770000
0.011.32%
Pre-Market: 7:12 AM EDT
15 minutes delayed
Comments
Loading...
BriaCell Therapeutics
BCTXNASDAQ
want to know what
the Bulls & Bears Say?
BriaCell Therapeutics (NASDAQ:BCTX) Stock, Analyst Ratings, Price Targets, Forecasts
BriaCell Therapeutics Corp has a consensus price target of $18 based on the ratings of 1 analysts. The high is $18 issued by HC Wainwright & Co. on June 4, 2024. The low is $18 issued by HC Wainwright & Co. on June 4, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on June 4, 2024, May 24, 2024, and December 28, 2023, respectively. With an average price target of $18 between HC Wainwright & Co., there's an implied 2237.66% upside for BriaCell Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for BriaCell Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/04/2024 | Buy Now | 2237.66% | HC Wainwright & Co. | Emily Bodnar | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2024 | Buy Now | 2237.66% | HC Wainwright & Co. | Emily Bodnar | → $18 | Reiterates | Buy → Buy | Get Alert |
| 12/28/2023 | Buy Now | 2237.66% | HC Wainwright & Co. | Emily Bodnar | → $18 | Reiterates | Buy → Buy | Get Alert |
| 10/03/2023 | Buy Now | 2497.4% | HC Wainwright & Co. | Emily Bodnar | $25 → $20 | Maintains | Buy | Get Alert |
| 06/28/2023 | Buy Now | 3146.75% | HC Wainwright & Co. | Emily Bodnar | → $25 | Reiterates | Buy → Buy | Get Alert |
| 02/24/2023 | Buy Now | 3146.75% | HC Wainwright & Co. | Emily Bodnar | → $25 | Reiterates | → Buy | Get Alert |
| 02/14/2022 | Buy Now | 3146.75% | HC Wainwright & Co. | Emily Bodnar | → $25 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for BriaCell Therapeutics (BCTX) stock?
The latest price target for BriaCell Therapeutics (NASDAQ:BCTX) was reported by HC Wainwright & Co. on June 4, 2024. The analyst firm set a price target for $18.00 expecting BCTX to rise to within 12 months (a possible 2237.66% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BriaCell Therapeutics (BCTX)?
The latest analyst rating for BriaCell Therapeutics (NASDAQ:BCTX) was provided by HC Wainwright & Co., and BriaCell Therapeutics reiterated their buy rating.
When was the last upgrade for BriaCell Therapeutics (BCTX)?
There is no last upgrade for BriaCell Therapeutics
When was the last downgrade for BriaCell Therapeutics (BCTX)?
There is no last downgrade for BriaCell Therapeutics.
When is the next analyst rating going to be posted or updated for BriaCell Therapeutics (BCTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BriaCell Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BriaCell Therapeutics was filed on June 4, 2024 so you should expect the next rating to be made available sometime around June 4, 2025.
Is the Analyst Rating BriaCell Therapeutics (BCTX) correct?
While ratings are subjective and will change, the latest BriaCell Therapeutics (BCTX) rating was a reiterated with a price target of $18.00 to $18.00. The current price BriaCell Therapeutics (BCTX) is trading at is $0.77, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.